Navigation Links
Next Breath Receives ISO/IEC 17025:2005 Accreditation from the American Association for Laboratory Accreditation
Date:2/19/2013

Baltimore, Maryland (PRWEB) February 19, 2013

Next Breath, LLC, a Specialty Contract Research Organization (CRO) with expertise in analytical testing of pulmonary, nasal drug, and ophthalmic delivery systems, announced today that the company received its ISO (the International Organization for Standardization) and IEC (the International Electrotechnical Commission) 17025:2005 accreditation from the American Association for Laboratory Accreditation (A2LA). Compliance with this standard provides a globally accepted basis for laboratory accreditation. The standard specifies the management and technical requirements to be met by testing and calibration laboratories in both the organization and management of quality.

The ISO/IEC 17025:2005 also covers testing and calibration performed using standard methods, non-standard methods, and laboratory-developed methods. This accreditation is another illustration of Next Breath’s commitment to quality and technical expertise, and adherence to the highest standards in quality management systems.

Julie Suman, President, says, “We are very pleased with this accreditation, which confirms Next Breath’s commitment to meeting and exceeding the highest quality standards. We work diligently to maintain regulatory standards and we have once again demonstrated our ability to sustain and continuously improve quality systems within our organization.”

About A2LA

A2LA is non-profit, non-governmental, public service, membership society. A2LA also offers programs for the accreditation of testing laboratories, calibration laboratories, inspection bodies, proficiency testing providers, medical testing laboratories, reference material producers and product certification bodies.

About Next Breath

Next Breath, a member of the AptarGroup, is a cGMP contract services organization for pharmaceutical, biotech and medical device companies that bring pulmonary, nasal, and ophthalmic drug products to market. Next Breath provides comprehensive solutions to the development processes from proof of concept to commercialization. Next Breath has led successful submissions for pulmonary and nasal drug products and devices in the US and international markets.

For more information please visit http://www.nextbreath.net or http://www.aptar.com

Contact Next Breath
Badre Hammond, MBA
+(1)352-642-2141 / badre(dot)hammond(at)nextbreath(dot)net

Read the full story at http://www.prweb.com/releases/2013/2/prweb10435177.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Breathe Better With Clarity Allergy Center
2. Medzilla.com Special Report: Unemployed Can Breathe a Little Freer After Supreme Court's Affordable Care Act Ruling
3. OsteoFab™ Patient Specific Cranial Device Receives 510(k) Approval
4. Discovery Labs Receives $30 Million Funding Commitment from Deerfield Management
5. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
6. OsteoVantage™ Receives Grant from the National Science Foundation
7. Avillion LLP Receives Initial Funding From Abingworth and Clarus
8. St. Mark’s School Receives $4.8 Million Gift from Tech Pioneer Graduate
9. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
10. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
11. BioNeutral Group Receives Positive Testing Results From A Global Independent Laboratory For Its Ygiene Sterilant Against Anthrax Spores
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 01, 2016 , ... ... long-term client Nanowear on their recent FDA Class II 510(k) clearance for their ... significant hurdle in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. ...
(Date:12/2/2016)... bioLytical Laboratories, a world leader in rapid infectious disease tests, introduced the Company,s newest ... members. (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , , bioLytical was invited ... introduce the INSTI HIV Self Test to 350 pharmacy representatives in Nairobi ...
(Date:11/30/2016)... Nov. 30, 2016 Biotest Pharmaceuticals Corporation (BPC), ... to announce the addition of its newest plasma collection ... Nebraska . The 15,200 square foot state-of-the-art facility ... 2016 and brings the total number of BPC,s plasma ... Carlisle , BPC,s Chief Executive Officer said "We are ...
(Date:11/30/2016)... November 2016   Merck , ein ... Unterzeichnung einer Reihe von Vereinbarungen mit Evotec ... AG Screeningleistungen für Mercks Palette genetischer Reagenzien ... auf diese Bibliotheken in Kombination mit Evotecs ... Weg zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
Breaking Biology Technology:
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
Breaking Biology News(10 mins):